↓ Skip to main content

Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure

Overview of attention for article published in Virology Journal, June 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (54th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
15 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure
Published in
Virology Journal, June 2015
DOI 10.1186/s12985-015-0323-3
Pubmed ID
Authors

Jiahong Yang, Gao Chen, Xuebing Chen, Hao Zhang, Di Jiang, Guang Yang

Abstract

Acute-on-chronic liver failure (ACLF) is a common serious hepatitis B virus (HBV)-related disease and has a poor prognosis. Until recently, initial combination antiviral treatment in ACLF patients was rarely reported. This study evaluated the effect of initial combination treatment with lamivudine and adefovir dipivoxil on the prognosis of HBV-related ACLF. In this retrospective study, 131 eligible ACLF patients, including 61 treated with 100 mg lamivudine and 10 mg adefovir dipivoxil daily and 70 not treated with any nucleoside analogs (NAs), were selected and assigned into the NA and non-NA groups. All the patients received standard medicinal therapy. At weeks 0-4 and 12, serum markers for hepatic and renal functions were measured in all patients and accumulated fatality rates were calculated. Statistical analyses, including Student's t test, χ (2) test and unconditional logistic regression analysis, were performed using SPSS version 17.0 software. Clinical data indicated that improvement of hepatic function was better in the NA than in the non-NA group. The accumulated fatality rate in the NA group was lower than in the non-NA group at weeks 2-4 and 12, and these differences were significant. Univariate analysis showed that age, prothrombin activity, model of end-stage liver disease (MELD) score, and treatment without NAs were risk factors for short-term survival of ACLF. Further research by unconditional logistic regression analysis identified that older age, high MELD score and treatment without NAs were independent risk factors for short-term survival of ACLF. Initial combination antiviral treatment is effective in decreasing short-term fatality of HBV-related ACLF.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 7%
Unknown 14 93%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 27%
Student > Postgraduate 2 13%
Researcher 2 13%
Other 1 7%
Librarian 1 7%
Other 1 7%
Unknown 4 27%
Readers by discipline Count As %
Medicine and Dentistry 9 60%
Agricultural and Biological Sciences 1 7%
Unknown 5 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 June 2015.
All research outputs
#2,405,327
of 5,273,580 outputs
Outputs from Virology Journal
#665
of 1,403 outputs
Outputs of similar age
#84,260
of 186,182 outputs
Outputs of similar age from Virology Journal
#23
of 49 outputs
Altmetric has tracked 5,273,580 research outputs across all sources so far. This one has received more attention than most of these and is in the 53rd percentile.
So far Altmetric has tracked 1,403 research outputs from this source. They receive a mean Attention Score of 3.3. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 186,182 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.